AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04534686 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CogXergaming
Description: The participant will play four of the six balance board games Table tilt, Tightrope, Soccer, Balance bubble, Light Run and Basic Step (each game is max 1.5 minutes). Each game will be superimposed with any 3 of the 6 cognitive tasks (word list generation consisting of verbal fluency (VF) and category fluency (CF), digit recall (DR), analogies (AN), mental arithmetic (MA), repeated letter (RL). The cognitive tasks will be randomized making sure that all the cognitive tasks are played with all the games. The cognitive and balance board game scores will be noted on the scoring sheet for each session. A total 10 minutes rest interval between every sub-session will be mandatorily provided.
Study NCT04534686 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Matter of Balance Training
Description: The program emphasizes practical coping strategies that include group discussions, mutual problem solving, exercises to improve strength, coordination and balance, and, a home safety evaluation.
Study NCT05326711 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telerehabilitation-based motor imagery training
Description: Telerehabilitation has been defined as the delivery of rehabilitation services through information and communication technologies.
Study NCT05557344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen IV
Description: An IV infusion of 15mg/kg of acetaminophen (PrACETAMINOPHEN INJECTION, AVIR Pharma Inc.) (maximum single dose:1g) will be administered regularly every 6h as a 15-minute intravenous infusion. At the same time, an oral placebo with similar appearance as the corresponding acetaminophen oral solution will be administered.
Study NCT05557344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: A liquid oral acetaminophen suspension will be administered regularly every 6h at a dose of 15mg/kg (maximum single dose: 1g). An IV infusion of NaCl 0.9% corresponding to the volume of IV acetaminophen will be administered as a 15-minute intravenous infusion at the same time as the oral dose. PrACETAMINOPHEN INJECTION ® is a clear and colorless liquid undistinguishable from NaCl 0.9%.
Study NCT05726578 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lung recruitment
Description: establishment of lung recruitment using high frequency ventilation and assessment with chest ultrasound and echocardiography
Study NCT04566328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given SC
Study NCT04566328 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Daratumumab and Hyaluronidase-fihj
Description: Given SC
Study NCT04566328 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab and Hyaluronidase-fihj
Description: Given SC
Study NCT04566328 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Given PO
Study NCT04566328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO
Study NCT04566328 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Given PO
Study NCT04566328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study NCT04566328 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04566328 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05864222 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aromatherapy
Description: Elequil Aroma-Tabs are available on all clinical nursing units for staff. Instructions will be provided to participants to place the aroma tab on the back of their badge every workday for the entire duration of their shift. They will wear their badge in whatever position is most comfortable to them for the duration of the study (6 months).
Study NCT05736549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine-Liposomal Bupivacaine
Description: A medication mixture of 40 ml (20 ml LB and 20 ml 0.25% plain bupivacaine) will be prepared, of which 20 ml will be used in Adductor canal block, 10 ml will be used in iPACK block and 5 ml each will be used in medial upper and lateral upper genicular nerve block, respectively.
Study NCT05736549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine -Dexamethasone Sodium Phosphate-Methylprednisolone Acetate
Description: A medication mixture of 40 ml (40 ml 0.25% plain bupivacaine, 10 mg DEX and 80 mg MPA) will be prepared, of which 20 ml will be used in Adductor canal block, 10 ml will be used in iPACK block and 5 ml each will be used in medial upper and lateral upper genicular nerve block, respectively.
Study NCT04306510 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood samples for immunoglobulins
Description: Following an injection of TEGSEDI as prescribed by their physician per the product label, patients will have additional blood tests at 1, 2, 4, 8 and 24 hours post injection for immunoglubulins at a clinic visit every 4 months for up to 2 years.
Study NCT04306510 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood samples for inflammatory markers
Description: Following an injection of TEGSEDI as prescribed by their physician per the product label, patients will have additional blood tests at 1, 2, 4, 8 and 24 hours post injection for inflammatory markers at a clinic visit every 4 months for up to 2 years.
Study NCT04306510 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood samples for anti-drug antibodies
Description: Patients taking TEGSEDI as prescribed by their physician per the product label, patients will have additional blood samples for anti-drug antibodies at various time-points as indicated in the event of hypersensitivity reactions.
Study NCT05227924 — intervention group
Intervention type: DEVICE
Intervention: Total hip arthroplasty (primary or revision)
Description: Total hip arthroplasty with at least one medical device from the SYMBOL range
Study NCT05152459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Given PO
Study NCT05152459 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ublituximab
Description: Given IV
Study NCT05152459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbralisib
Description: Given PO
Study NCT04859088 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Partial Enteral Nutrition
Description: Dietary intervention (Liquid food replacement intervention)
Study NCT05279859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ERAS-007
Description: Administered orally
Study NCT05279859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ERAS-601
Description: Administered orally
Study NCT05279859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Administered orally
Study NCT05682742 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic-assisted Surgery
Description: Subjects scheduled to undergo robotic-assisted surgery
Study NCT06169553 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Holistic injection-related injection treatment
Description: Participants in the intervention group will be provided additional supports to address their social and medical needs, including infectious disease management, addictions medicine, peer support, and systems navigation. Each participant will receive individualized care depending on their unique needs.
Study NCT05315479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N1539
Description: Once daily
Study NCT01329081 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postoperative rehabilitation after fast-track TKA
Description: Six weeks of strength training combined with patient education
Study NCT01329081 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postoperative rehabilitation after fast-track TKA
Description: Six to eight weeks of supervised home training
Study NCT03128775 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nudge
Description: School lunchrooms are the central place of modifications regarding food consumption, where the following strategies will be conducted:~1. arrange the fruits served in the school lunch in a prominent position, in containers of bright and contrasting colors to serve them;~2. Create creative names for food served at meals will be created by the students used on displays at canteen tables, posters on the way of the cafeteria and at a menu outside the cafeteria.~To encourage water consumption, footprints that lead to them to water fountains will be painted on the floor. To stimulate physical activity, several sports equipment (basketball hoops, volleyball nets, balls, ropes, shuttlecock and a lot of toys) will be available for use in the school sports court. The courts will be renovated and footsteps painted in order to nudging students to the sports equipment.
Study NCT03128775 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Primary prevention
Description: Classroom-based educational activities based on an earlier study, called PAPPAS, which was developed in the same city and constituted a school-based intervention with the objective of reducing the consumption of sweetened beverages and biscuits and increase the consumption of fruits, vegetables and beans. Activities will be facilitated by trained research assistants. Printed instructions and orientations on the facilitation process will support the assistants' efforts. The activities will require 20 to 30 minutes, and teachers will be encouraged to reiterate the message during their lesson. The goal is to promote ten one-hour sessions of activity for each class.
Study NCT03128775 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Primary prevention + nudge
Description: This group will receive both primary prevention and nudge activities. At school lunchrooms, the fruits served in the school lunch will be put in a prominent position, in containers of bright and contrasting colors to serve them; create creative names for food served at meals will be created by the studentes, footprints that lead to them to water fountains will be painted on the floor. Several sports equipment (basketball hoops, volleyball nets, balls, ropes, shuttlecock and a lot of toys) will be available for use in the schools sport court. Also, classroom-based educational activities based on an earlier study, called PAPPAS, will be held. The activities will require 20 to 30 minutes, and teachers will be encouraged to reiterate the message during their lesson. The goal is to promote ten one-hour sessions of activity for each class.
Study NCT05837884 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: blood sampling
Description: Participants will provide a blood sample that will be used to determine whether they have a monoclonal protein
Study NCT05022810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: New Paracetamol Oral Suspension (24 mg/ml)
Description: After an overnight fasting for at least 10 hours, New Paracetamol Oral Suspension (24 mg/ml) in a volume of 42 ml will be administered orally via a single use syringe by a trained study person to the study participants as per the randomization schedule in each period.
Study NCT05022810 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Panadol B&I Oral Suspension (24 mg/ml paracetamol)
Description: After an overnight fasting for at least 10 hours, Panadol B\&I Oral Suspension (24 mg/ml paracetamol) in a volume of 42 ml will be administered orally via a single use syringe by a trained study person to the study participants as per the randomization schedule in each period.
Study NCT04259190 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: interoceptive exposure
Description: Repeated 60-second trials of voluntary hyperventilation, each followed by a 15-second rest period. Participants will complete a minimum of 8 trials and continue additional trials until ratings of their most feared predicted outcome fall less than or below 5% likelihood.
Study NCT04259190 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: interoceptive exposure
Description: Repeated 60-second trials of voluntary hyperventilation, each followed by a 15-second rest period. Participants will complete a minimum of 8 trials and continue additional trials until ratings of their most feared predicted outcome fall less than or below 5% likelihood.
Study NCT06651489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Subcutaneous injection of 100 mg at Weeks 0, 4, 12, and 20
Study NCT06650826 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Determination of anti-platelet factor 4 antibodies in the blood
Description: The anti-platelet factor 4 antibodies in the blood are determined using latex agglutination and the chemiluminescence method in the coagulation laboratory of the CCB MVZ laboratory. In addition, the platelet factor 4-induced platelet activation test (PIPA test) and the heparin-induced platelet activation test (HIPA test) as well as an ELISA-based platelet factor 4 IgG antibody test (Prof. Greinacher, Greifswald University Hospital) will be performed as part of the routine work up.~In addition a new assay for heparin-independent anti-PF4 antibody detection provided by the company Werfen using chemiluminescence will be performed.
Study NCT06651307 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lifting with elbow sleeves
Description: Lifting with elbow sleeves
Study NCT06164886 — intervention group
Intervention type: OTHER
Intervention: Waiting list
Description: patient on the waiting list for scheduled surgical admissions
Study NCT06198192 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates Exercises
Description: Ten repetitions of Pilates exercises will be performed with a 2-minute rest period between repetitions. Pilate group will receive the intervention program three times/week for total 10 weeks
Study NCT06198192 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Therapy and Balance Exercises
Description: this group receive conventional therapy along with balance exercises. Standing with feet together while the therapist sitting behind and manually locking the child knees, and then slowly tilt him to each side, forward and backward. Step standing with therapist behind the child guiding him to shift his weight forward then backward alternately. High step standing and try to keep balanced. Standing with manual locking of the knees then tries actively to stoop and recover. Equilibrium, righting and protective reactions training. Open environment gait training will be conducted with the different obstacles. Session includes three times/week for total 10 weeks
Study NCT06147856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mRNA-3210
Description: IV infusion
Study NCT06650020 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: synchronous online learning
Description: Each participant in this cohort selected a suitable and peaceful learning environment, characterized by ample lighting and strong network connectivity. Equipped with laptops, participants logged into the Tencet conference software ten minutes prior to the session, entered their authentic names, completed the sign-in process five minutes before the course started, and kept their cameras activated throughout the session. During the instructional phase, both the teacher and control group were physically present. While the teacher instructed the control group, screen sharing through Tencet conference software allowed trainees in the experimental group to have clear visual access to instructional materials while audibly receiving instruction through microphones.
Study NCT06650020 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the traditional offline model of centralized training
Description: The control group adhered to the traditional offline model of centralized training, which involved a training facility spanning 100 square meters and accommodating seating for 150 participants. The front section of the training room was equipped with various amenities, such as a projection screen, podium, computer, and microphone, all available for use by the instructors. Throughout the training period, the lecturer provided in-person instruction on-site, allowing trainees to engage in real-time interaction by raising their queries.
Study NCT06060574 — intervention group
Intervention type: DEVICE
Intervention: Platelet rich fibrin device
Description: Within the scope of the study, a total of 2 tubes of venous blood samples will be obtained from the forearm region (antecubital vein) of each individual by the clinical staff specialist nurse of the Department of Periodontology. PRF samples will be created using appropriate equipment and devices from blood samples obtained from each individual. In the study, 10 ml glass-coated plastic tubes will be used. Apart from this, 5 mL of blood taken will be used for complete blood count and evaluation of hormones on the relevant day.~PRF Preparation: In all age groups, PRF will be prepared by centrifugation with 700xg (=2700 rpm, Intra-Spin L-PRF device) for 12 minutes.
Study NCT05109169 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: FINGER 2.0 multidomain lifestyle-based intervention
Description: Multimodal lifestyle-based precision prevention intervention, including:~* Optimized FINGER multidomain lifestyle intervention (diet, physical activity, cognitive training and cardiovascular/metabolic risk monitoring and social interaction)~* Metformin (Glucophage® XR)
Study NCT05109169 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Self-guided multidomain lifestyle intervention
Description: Participants build their own healthy lifestyle program based on standard healthy lifestyle advice on diet, physical activity, cognitive training and cardiovascular/metabolic risk
Study NCT06540144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rozanolixizumab
Description: rozanolixizumab solution for injection
Study NCT05198791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stratified medicine - Microvascular dysfunction and eplerenone therapy, tablets
Description: Stratified medicine including interventional diagnostic procedure (IDP) and linked treatment with eplerenone. Patients with an increased IMR (strata with microvascular dysfunction, IMR ≥25) will be eligible for randomization to this arm. Patients randomized to receive eplerenone will be commenced on 25 mg once daily, and uptitrated to 50 mg once daily after two weeks. Treatment will be continued for a period of six months.
Study NCT04972318 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positive end-expiratory pressure titration with driving pressure control
Description: Positive end-expiratory pressure will be tailored during a decremental maneuver (without a formal alveolar recruitment maneuver). The best positive end-expiratory pressure will be defined as the one associated with the higher respiratory system compliance, up to 20 cmH2O. Plateau pressure limit will be 30 cmH2O. If driving pressure remains elevated after optimal PEEP setting, tidal volume will be reduced to keep driving pressure below 14 cmH2O.
Study NCT05198791 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Stratification and standard care
Description: Interventional diagnostic procedure (IDP) without linked treatment i.e., standard care. Patients with an increased IMR (strata with microvascular dysfunction, IMR ≥25) will be eligible for randomization to this arm. In the standard care group, the IDP is performed but the results are not disclosed. The IDP is therefore a sham procedure. Patients randomized to receive eplerenone will be commenced on 25 mg once daily, and uptitrated to 50 mg once daily after two weeks. Treatment will be continued for a period of six months.
Study NCT05093699 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Butterfly iQ+ ultrasound probe
Description: Diagnostic ultrasound probe on-market (FDA approved) capable of dual-plane viewing
Study NCT05093699 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound probe
Description: Standard single-view ultrasound probe
Study NCT04792112 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision support tool
Description: Decision support tool for late preterm antenatal corticosteroids
Study NCT05126927 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 68Ga-NODAGA-SNA006
Description: A PET contrast agent to assess the level of tumor tissue-infiltrating CD8 + T cells in patients with solid tumors
Study NCT06096909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafolecimab
Description: The PCSK9 mAb in this study is defined as Tafolecimab 150mg q2w subcutaneously. For the two groups of lipid-lowering regimens, the lipid-lowering drug regimens other than PCSK9 mAb were maintained throughout the study as much as possible in accordance with the guidelines related to blood lipids, provided that no serious safety problems occurred.
Study NCT06096909 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholesterol Absorption Inhibitor
Description: Cholesterol absorption inhibitors (like Ezetimibe and Hybutimibe) are based on physician decisions, but need to be routinely dosed. Examples of Medications that Meet Study Requirements: Ezetimibe 10mg Po qd.
Study NCT06096909 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Statin
Description: Statin are based on physician decisions, but need to be routinely dosed. Examples of Medications that Meet Study Requirements: Atorvastatin 20mg Po qn, Rosuvastatin 10mg Po qn or Pitavastatin 4mg Po qn.
Study NCT06096909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statin
Description: Statin are based on physician decisions, but need to be routinely dosed. Examples of Medications that Meet Study Requirements: Atorvastatin 20mg Po qn, Rosuvastatin 10mg Po qn or Pitavastatin 4mg Po qn.